REGN Q1 2024 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$81B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3.1B-0.5% YoY

Gross Profit

$2.7B86.2% margin

Operating Income

$751M23.9% margin

Net Income

$722M23.0% margin

EPS (Diluted)

$6.27

QoQ Revenue Growth

-8.4%

Cash Flow

Operating Cash Flow

$1.5B

Free Cash Flow

$1.4B

Stock-Based Comp.

$230M

Balance Sheet

Total Assets

$34.4B

Total Liabilities

$7.4B

Stockholders' Equity

$27.0B

Cash & Equivalents

$2.6B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.1B	$3.2B	-0.5%
Gross Profit	$2.7B	$2.6B	+4.1%
Operating Income	$751M	$1.0B	-25.1%
Net Income	$722M	$818M	-11.7%

Revenue Segments

Product

$1.8B56%

Collaboration Revenue

$1.3B40%

Product and Service, Other

$117M4%